Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 387,679,040
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.58
  • Price/Sales 5.07
  • Price/Cash Flow 15.12
  • Price/Book 6.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.95
  • Number of Estimates 7
  • High Estimate 1.97
  • Low Estimate 1.93
  • Prior Year 1.74
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.05 +8.10%
on 10/25/18
146.75 -0.52%
on 11/13/18
+9.43 (+6.91%)
since 10/16/18
3-Month
132.19 +10.44%
on 08/17/18
146.75 -0.52%
on 11/13/18
+13.51 (+10.20%)
since 08/16/18
52-Week
118.62 +23.07%
on 05/29/18
148.32 -1.57%
on 01/17/18
+7.12 (+5.13%)
since 11/16/17

Most Recent Stories

More News
ACUVUE® OASYS with Transitions(TM) Light Intelligent Technology(TM) Named in TIME's 'Best Inventions of 2018'

First-of-its-kind[i] contact lens corrects vision and adapts to changing light conditions to enhance comfort and performance in everyday life

JNJ : 145.99 (+1.03%)
ACUVUE® OASYS with Transitions(TM) Light Intelligent Technology(TM) Named in TIME's 'Best Inventions of 2018'

TIME has selected ACUVUE® OASYS with Transitions(TM) Light Intelligent Technology(TM) as one of the 'Best Inventions of 2018,' in its annual round-up spotlighting groundbreaking innovations worldwide....

JNJ : 145.99 (+1.03%)
Janssen receives positive CHMP opinion for ERLEADA(TM) (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease

--The major efficacy outcome was supported by statistically significant improvements for secondary endpoints, including time to metastasis, progression-free survival, and time to symptomatic progression(1)...

JNJ : 145.99 (+1.03%)
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'

First-of-its-kind contact lens corrects vision and adapts to changing light conditions

JNJ : 145.99 (+1.03%)
CHPA Educational Foundation Holds Third Annual Gala; Announces New Board Member

The Consumer Healthcare Products Association (CHPA) Educational Foundation held its fall board meeting and third annual gala on November 13, 2018 in New York City. The gala celebrates the...

ABC : 88.75 (-0.45%)
JNJ : 145.99 (+1.03%)
Markets Right Now: Stocks erase early loss, finish higher

NEW YORK (AP) — The latest on developments in financial markets (all times local):

JNJ : 145.99 (+1.03%)
Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JNJ : 145.99 (+1.03%)
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

JNJ : 145.99 (+1.03%)
MRK : 76.06 (+1.63%)
LLY : 113.83 (+1.45%)
ABBV : 91.53 (+1.54%)
Janssen Seeks Expanded Use of IMBRUVICA(R) (ibrutinib) in Two Indications in Europe

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for...

JNJ : 145.99 (+1.03%)
2018-2023 Vision Care Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast

VRX.TO : 30.80 (-3.33%)
LUXTY : 61.4000 (+1.47%)
JNJ : 145.99 (+1.03%)
HOCPF : 59.0000 (+4.61%)
NVS : 87.75 (+0.58%)
FLMNY : 13.3000 (-20.50%)
TOPCF : 14.0500 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 147.95
1st Resistance Point 146.97
Last Price 145.99
1st Support Level 144.78
2nd Support Level 143.57

See More

52-Week High 148.32
Last Price 145.99
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar